Search Result

Results for "

diet-induced obese (DIO)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amine N-methyltransferase (4) Amylin Receptor (3) Bombesin Receptor (2) Cannabinoid Receptor (1) Casein Kinase (1) CGRP Receptor (1) Collagen (1) COX (1) Cytochrome P450 (2) ELOVL (1) Endogenous Metabolite (1) Enteropeptidase (2) Free Fatty Acid Receptor (1) FXR (1) GCGR (3) GLP Receptor (3) Glucokinase (2) JNK (1) MCHR1 (GPR24) (2) Melanocortin Receptor (1) Neurokinin Receptor (1) Neuropeptide Y Receptor (1) NF-κB (1) NOD-like Receptor (NLR) (1) PGC-1α (1) Reference Standards (1) Sirtuin (1) Sodium Channel (1) TGF-β Receptor (1)
By Research Areas:	Endocrinology (1) Inflammation/Immunology (2) Metabolic Disease (27) Neurological Disease (1)

By Targets:

Amine N-methyltransferase (4)

Amylin Receptor (3)

Bombesin Receptor (2)

Cannabinoid Receptor (1)

Casein Kinase (1)

CGRP Receptor (1)

Collagen (1)

COX (1)

Cytochrome P450 (2)

ELOVL (1)

Endogenous Metabolite (1)

Enteropeptidase (2)

Free Fatty Acid Receptor (1)

FXR (1)

GCGR (3)

GLP Receptor (3)

Glucokinase (2)

JNK (1)

MCHR1 (GPR24) (2)

Melanocortin Receptor (1)

Neurokinin Receptor (1)

Neuropeptide Y Receptor (1)

NF-κB (1)

NOD-like Receptor (NLR) (1)

PGC-1α (1)

Reference Standards (1)

Sirtuin (1)

Sodium Channel (1)

TGF-β Receptor (1)

By Research Areas:

Endocrinology (1)

Inflammation/Immunology (2)

Metabolic Disease (27)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10745

Petrelintide ZP8396	Amylin Receptor	Metabolic Disease
Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research .

HY-P10745A

Petrelintide acetate ZP8396 acetate	Amylin Receptor	Metabolic Disease
Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research .

HY-12443

PF-5006739	Casein Kinase	Neurological Disease
PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC₅₀s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .

HY-151500

JBSNF-000028 free base	Amine N-methyltransferase	Metabolic Disease
JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC₅₀ values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC₅₀ being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .

HY-160912

ELOVL6-IN-5	ELOVL	Metabolic Disease
ELOVL6-IN-5 is an orally active and selective elongase enzyme of long-chain fatty acid family 6 (ELOVL6) inhibitor with IC₅₀values of 85 nM and 38 nM for human and mouse ELOVL6, respectively. ELOVL6-IN-5 shows >60-fold selectivity over other ELOVL family enzymes (ELOVL1, 2, 3, 5) and no effect on other lipid synthesis enzymes like ACC1, ACC2. ELOVL6-IN-5 reduces hepatic fatty acid composition ratio of C18 to C16 in diet-induced obesity (DIO) and KKAy mice. ELOVL6 inhibition by ELOVL6-IN-5 does not improve insulin resistance. ELOVL6-IN-5 can be used for the research of metabolic disease .

HY-13467

AM-1638 3 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
AM-1638 is an orally active full agonist of GPR40 (EC₅₀: 0.16 μM). AM-1638 increases the expression of antioxidant molecules (HO-1 and NQO-1). AM1638 blocks Palmitate (HY-N0830)-mediated superoxide production and ER stress. AM-1638 has antidiabetic activity and improves glycemic control in BDF mice with diet-induced obesity (DIO). AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%) .

HY-14342

MK-5046 2 Publications Verification	Bombesin Receptor	Metabolic Disease
MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC₅₀ and an EC₅₀ value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .

HY-114557

NSC 90469 3,5-Diiodo-L-thyronine	JNK NF-κB Sirtuin PGC-1α COX TGF-β Receptor Collagen	Metabolic Disease Inflammation/Immunology Endocrinology
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic *Dio1* activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .

HY-P10032

NN1177 NNC9204-1177	GCGR GLP Receptor Cytochrome P450	Metabolic Disease
NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-151500B

JBSNF-000028 hydrochloride	Amine N-methyltransferase	Metabolic Disease
JBSNF-00002 hydrochloride is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC₅₀ values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 hydrochloride can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC₅₀ being 2.5 μM. JBSNF-00002 hydrochloride exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 hydrochloride can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .

HY-161297

NT-0249	NOD-like Receptor (NLR)	Inflammation/Immunology
NT-0249 is an orally active NLRP3 inhibitor. NT-0249 has anti-inflammatory activity

HY-151500A

JBSNF-000028 TFA	Amine N-methyltransferase	Metabolic Disease
JBSNF-00002 TFA is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC₅₀ values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 TFA can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC₅₀ being 2.5 μM. JBSNF-00002 TFA exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 TFA can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .

HY-144287

Glucokinase activator 3	Glucokinase Sodium Channel	Metabolic Disease
Glucokinase activator 3 is an orally active Glucokinase (GK) activator with an AC₅₀ of 38 nM. Glucokinase activator 3 inhibits hERG channel and sodium channel in patch clamp assays. Glucokinase activator 3 exhibits high efficacy in reducing blood glucose in diet-induced obese (DIO) mice. Glucokinase activator 3 has the potential for the research of type 2 diabetes .

HY-14342A

(R)-MK-5046	Bombesin Receptor	Metabolic Disease
(R)-MK-5046 is the isomer of MK-5046 (HY-14342), and can be used as an experimental control. MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC₅₀ and an EC₅₀ value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .

HY-151500C

JBSNF-000028	Amine N-methyltransferase	Metabolic Disease
JBSNF-00002 is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC₅₀ values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC₅₀ being 2.5 μM. JBSNF-00002 exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .

HY-177297

LCZ960 NVP-LCZ960	Glucokinase	Metabolic Disease
LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .

HY-101699A

AMG-076	MCHR1 (GPR24)	Metabolic Disease
AMG-076 is an orally bioavailable and selective MCHR1 antagonist. AMG-076 results in significant reduction in body weight gain in nonobese mice fed a high-fat diet and in high-fat diet-induced obese (DIO) mice .

HY-101699

AMG-076 free base	MCHR1 (GPR24)	Metabolic Disease
AMG-076 free base is an orally bioavailable and selective MCHR1 antagonist. AMG-076 free base results in significant reduction in body weight gain in nonobese mice fed a high-fat diet and in high-fat diet-induced obese (DIO) mice .

HY-178857

CB1 antagonist 6	Cannabinoid Receptor	Metabolic Disease
CB1 antagonist 6 (Compound 11jE2) is an orally active CB1R antagonist, with an IC₅₀ value of 23 nM. CB1 antagonist 6 significantly reduces food intake and body weight, improves glucose tolerance and insulin resistance, and decreases serum ALT and AST levels in diet-induced obese (DIO) mice, demonstrating hepatoprotective effects. CB1 antagonist 6 can be used for the study of metabolic syndrome (obesity, diabetes) .

HY-P11262

GUB021794	GLP Receptor	Metabolic Disease
GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC₅₀ value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC₅₀ value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes .

HY-113567

GSK2324	FXR	Metabolic Disease
GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC₅₀ of 120 nM. GSK2324 exhibits t_1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively .

HY-111131

RY764	Melanocortin Receptor	Metabolic Disease
RY746 is a selective MC4R agonist, with an EC₅₀ of 10 nM. RY764 effectively inhibits food intake and reduces body weight gain in diet-induced obese (DIO) rat models. RY764 can be used for the study of obesity .

HY-P10032A

NN1177 TFA NNC9204-1177 TFA	GCGR Cytochrome P450 GLP Receptor	Metabolic Disease
NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-147927

Human enteropeptidase-IN-1	Enteropeptidase	Metabolic Disease
Human enteropeptidase-IN-1 (compound 6b) is a highly potent, orally active and low systemic exposure enteropeptidase inhibitor. Human enteropeptidase-IN-1 boosts the increase in fecal protein output, and exhibits potent body weight loss in diet-induced obese (DIO) rat model. Human enteropeptidase-IN-1 can be used for anti-obesity research .

HY-147927A

(S)-Human enteropeptidase-IN-1	Enteropeptidase	Metabolic Disease
(S)-Human enteropeptidase-IN-1 (Compound 6c) is an orally active enteropeptidase inhibitor with low systemic exposure (IC₅₀ (initial): 26 nM; IC₅₀ (app): 1.8 nM). (S)-Human enteropeptidase-IN-1 promotes increased fecal protein output and effectively reduces body weight in a diet-induced obese (DIO) rat model. (S)-Human enteropeptidase-IN-1 inhibits enteropeptidase via a reversible covalent mechanism and prolongs the enzyme inactivation time. (S)-Human enteropeptidase-IN-1 can be used in anti-obesity research .

HY-114557R

NSC 90469 (Standard) 3,5-Diiodo-L-thyronine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
NSC 90469 (Standard) is the analytical standard of NSC 90469. This product is intended for research and analytical applications. NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic *Dio1* activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .

HY-P11044

GEP12	GCGR Neuropeptide Y Receptor	Metabolic Disease
GEP12 is a GLP-1R/Y1-R/Y2-R tri-receptor agonist peptide with an EC₅₀ of 17.3 nM and an IC₅₀ of 19.2 nM for receptor binding. GEP12 may promote glycemic control and weight loss .

HY-P11075

[Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10)	Neurokinin Receptor	Metabolic Disease
[Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) (ID 305) is a selective NK2R agonist with an EC₅₀ of 3.7  nM for hNK2R. [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) significantly inhibits weight loss in diet-induced obese (DIO) mice model and improves Loperamide (HY-156131)-induced dysfunctional voiding in wild-type mice. [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) can be used for neurokinin receptor mediated disorders, such as obesity, insulin resistance and type 2 diabetes research .

HY-P11587

BGM1812	Amylin Receptor CGRP Receptor	Metabolic Disease
BGM1812 is a dual agonist of amylin (hAMY3R) (EC₅₀ = 0.627 nM) and CGRP Receptor (hCTR) (EC₅₀ = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity .

Cat. No.	Product Name	Target	Research Area